As we previously reported, the parties in the follow-on Amgen v. Apotex BPCIA litigation concerning Apotex’s proposed biosimilars of NEUPOGEN (filgrastim) and NEULASTA (pegfilgrastim) informed the district court on August 8 that they were drafting a stipulation and unopposed motion that would substitute Apotex as a party with a then-unnamed entity. On August 26, the district court issued an order substituting Accord BioPharma for Apotex as the defendant in the action. Accord is a subsidiary of Intas Pharmaceuticals, which jointly developed the proposed filgrastim and pegfilgrastim biosimilars with Apotex.
